(HealthDay News) — For patients with type 2 diabetes, basal insulin peglispro provides better glycemic control than insulin glargine, with increased triglycerides, aminotransferases, and liver fat content, according to a study published in Diabetes Care.
John B. Buse, MD, PhD, from the University of North Carolina School of Medicine in Chapel Hill, and colleagues conducted a 52-week trial to examine the efficacy and safety of basal insulin peglispro vs insulin glargine in patients with type 2 diabetes.
Patients with a mean HbA1c of 7.42% were randomly assigned to basal insulin peglispro (n=307) or glargine (n=159).
The researchers found the reduction in HbA1c to be superior with basal insulin peglispro vs glargine at 26 weeks (–0.82% vs −0.29%; P<.001); the greater reduction with basal insulin peglispro was maintained at 52 weeks.
At weeks 26 and 52, more basal insulin peglispro patients achieved HbA1c <7% (P<.001). Nocturnal hypoglycemia was 60% lower with basal insulin peglispro vs glargine; furthermore, HbA1c <7% was achieved without nocturnal hypoglycemia in more patients at 26 and 52 weeks (P<.001), and total hypoglycemia rates were lower at 52 weeks (P=.03) for basal insulin peglispro.
For basal insulin peglispro vs glargine, glucose variability was lower, basal insulin dose was higher, and triglycerides and aminotransferases were higher at weeks 26 and 52.
“[Basal insulin peglispro] provided superior glycemic control vs glargine, with reduced nocturnal and total hypoglycemia, lower glucose variability, and increased triglycerides, aminotransferases, and liver fat content,” the researchers wrote.
Several authors disclosed financial ties to pharmaceutical companies, including Eli Lilly, which funded the study.